Curve Biosciences

Curve Biosciences is a company dedicated to the precise treatment of chronic diseases, with products targeting tissue biological changes that cause the development and progression of chronic diseases. Curve's Chronic Disease Tissue Atlas (CDTA) enables the company to discover these precise changes through data from over 250,000 tissues across more than 1,000 clinical studies. Curve is focused on commercializing its first-class blood test for the $30 billion chronic liver disease market while leveraging the CDTA to identify biomarkers and targets for other diseases.